Health Technology · Pharmaceuticals: Major · NSE: JUBLPHARMA · data 2026-10-09
Jubilant Pharmova Limited
Health check: Average (4.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹931.9
Market cap
₹14,849 cr
P/E
42
P/B
—
ROE
6.0%
ROCE
6.5%
Debt / equity
0.51
Dividend yield
0.54%
1-year return
-14.1%
52-week high
₹1,184.8
52-week low
₹786.05
Operating margin
8.7%
Growth
| Revenue (last 12 months) | ₹8,608 cr |
| Net profit (last 12 months) | ₹352 cr |
| Sales growth, 3 years (yearly) | 9.7% |
| Profit growth, 3 years (yearly) | — |
Chart patterns
- Golden cross — breakout (key level ₹957.84)
Similar companies
Alembic Pharmaceuticals Limited (APLLTD) · NATCO Pharma Limited (NATCOPHARM) · AstraZeneca Pharma India Limited (ASTRAZEN) · Indegene Limited (INDGN) · Marksans Pharma Limited (MARKSANS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open JUBLPHARMA in NSE Scanner →